Jazz Pharmaceuticals Acquires Actio Biosciences
Jazz Pharmaceuticals acquires ABS-1230, a first-in-class precision therapy for KCNT1-related epilepsy, strengthening its rare disease pipeline.
Renee Gala | 16/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy